LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced Acetylcysteine Solution, USP, 10% in multiple presentations – 4 mL, 10 mL and 30 mL vials – with immediate availability. Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.
Until recently, Acetylcysteine Solution, USP vial for inhalation (mucolytic agent) or oral administration (acetaminophen antidote) has been on the drug-shortage lists maintained by both the U.S. Food and Drug Administration and the American Society of Health-System Pharmacists.
With the introduction of Acetylcysteine Solution, USP, 10%, Fresenius Kabi now offers the largest portfolio of Acetylcysteine Solution products. Fresenius Kabi also offers an Acetylcysteine 20% portfolio comprising 4 mL, 10 mL and 30 mL vials.
“Since 2008, Fresenius Kabi has responded multiple times and in a variety of ways to meet clinician and patient needs due to U.S. drug shortages,” said John Ducker, president and CEO of Fresenius Kabi USA. “The introduction of Acetylcysteine 10% is another example of our commitment to provide needed products in convenient presentations.”
About Acetylcysteine Solution, USP, 10%
For inhalation, Acetylcysteine, a mucolytic agent, is used as adjuvant therapy for patients with certain lung diseases including chronic and acute bronchopulmonary disease. Inhalation therapy reduces the viscosity of mucus, thinning mucus secretions. When administered orally, it is indicated as an antidote to prevent or lessen hepatic injury following acetaminophen overdose. Acetylcysteine Solution, USP, is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as:
- Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung)
- Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis)
- Pulmonary complications of cystic fibrosis
- Tracheostomy care
- Pulmonary complications associated with surgery
- Use during anesthesia
- Post-traumatic chest conditions
- Atelectasis due to mucous obstruction
- Diagnostic bronchial studies (bronchgrams, bronchospirometry, and bronchial wedge catheterization)
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. For more information about Fresenius Kabi worldwide, please visit www.fresenius-kabi.com.
